FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3173641743> ?p ?o ?g. }

• W3173641743 endingPage "1255" @default.
• W3173641743 startingPage "1245" @default.
• W3173641743 abstract "The phase III CLinical Evaluation Of Pertuzumab And TRAstuzumab (CLEOPATRA) trial established the combination of pertuzumab, trastuzumab and docetaxel as standard first-line therapy for human epidermal growth factor receptor 2 (HER2)-positive locally recurrent/metastatic breast cancer (LR/mBC). The multicentre single-arm PERtUzumab global SafEty (PERUSE) study assessed the safety and efficacy of pertuzumab and trastuzumab combined with investigator-selected taxane in this setting.Eligible patients with inoperable HER2-positive LR/mBC and no prior systemic therapy for LR/mBC (except endocrine therapy) received docetaxel, paclitaxel or nab-paclitaxel with trastuzumab and pertuzumab until disease progression or unacceptable toxicity. The primary endpoint was safety. Secondary endpoints included progression-free survival (PFS) and overall survival (OS). Prespecified subgroup analyses included subgroups according to taxane, hormone receptor (HR) status and prior trastuzumab. Exploratory univariable analyses identified potential prognostic factors; those that remained significant in multivariable analysis were used to analyse PFS and OS in subgroups with all, some or none of these factors.Of 1436 treated patients, 588 (41%) initially received paclitaxel and 918 (64%) had HR-positive disease. The most common grade ≥3 adverse events were neutropenia (10%, mainly with docetaxel) and diarrhoea (8%). At the final analysis (median follow-up: 5.7 years), median PFS was 20.7 [95% confidence interval (CI) 18.9-23.1] months overall and was similar irrespective of HR status or taxane. Median OS was 65.3 (95% CI 60.9-70.9) months overall. OS was similar regardless of taxane backbone but was more favourable in patients with HR-positive than HR-negative LR/mBC. In exploratory analyses, trastuzumab-pretreated patients with visceral disease had the shortest median PFS (13.1 months) and OS (46.3 months).Mature results from PERUSE show a safety and efficacy profile consistent with results from CLEOPATRA and median OS exceeding 5 years. Results suggest that paclitaxel is a valid alternative to docetaxel as backbone chemotherapy. Exploratory analyses suggest risk factors that could guide future trial design." @default.
• W3173641743 created "2021-07-05" @default.
• W3173641743 creator A5000525925 @default.
• W3173641743 creator A5000676746 @default.
• W3173641743 creator A5001197670 @default.
• W3173641743 creator A5001211980 @default.
• W3173641743 creator A5001231739 @default.
• W3173641743 creator A5001649742 @default.
• W3173641743 creator A5001676964 @default.
• W3173641743 creator A5001835378 @default.
• W3173641743 creator A5002193456 @default.
• W3173641743 creator A5002300591 @default.
• W3173641743 creator A5002381363 @default.
• W3173641743 creator A5002388683 @default.
• W3173641743 creator A5002621278 @default.
• W3173641743 creator A5002647602 @default.
• W3173641743 creator A5002802780 @default.
• W3173641743 creator A5003082935 @default.
• W3173641743 creator A5003113119 @default.
• W3173641743 creator A5003897511 @default.
• W3173641743 creator A5003969811 @default.
• W3173641743 creator A5003986313 @default.
• W3173641743 creator A5004207547 @default.
• W3173641743 creator A5005902146 @default.
• W3173641743 creator A5005973748 @default.
• W3173641743 creator A5006337734 @default.
• W3173641743 creator A5006642161 @default.
• W3173641743 creator A5006721170 @default.
• W3173641743 creator A5007290313 @default.
• W3173641743 creator A5007528225 @default.
• W3173641743 creator A5007834158 @default.
• W3173641743 creator A5007978312 @default.
• W3173641743 creator A5008140774 @default.
• W3173641743 creator A5008322636 @default.
• W3173641743 creator A5009056091 @default.
• W3173641743 creator A5009059697 @default.
• W3173641743 creator A5009063394 @default.
• W3173641743 creator A5009247132 @default.
• W3173641743 creator A5009861042 @default.
• W3173641743 creator A5009976972 @default.
• W3173641743 creator A5010028400 @default.
• W3173641743 creator A5010090604 @default.
• W3173641743 creator A5011187215 @default.
• W3173641743 creator A5012065709 @default.
• W3173641743 creator A5012424242 @default.
• W3173641743 creator A5012827037 @default.
• W3173641743 creator A5012884004 @default.
• W3173641743 creator A5013477981 @default.
• W3173641743 creator A5013531637 @default.
• W3173641743 creator A5013541693 @default.
• W3173641743 creator A5013607872 @default.
• W3173641743 creator A5013942634 @default.
• W3173641743 creator A5015052494 @default.
• W3173641743 creator A5015117771 @default.
• W3173641743 creator A5015824949 @default.
• W3173641743 creator A5016011073 @default.
• W3173641743 creator A5016639606 @default.
• W3173641743 creator A5016923385 @default.
• W3173641743 creator A5017555080 @default.
• W3173641743 creator A5018307270 @default.
• W3173641743 creator A5018564985 @default.
• W3173641743 creator A5019053015 @default.
• W3173641743 creator A5019110582 @default.
• W3173641743 creator A5019516632 @default.
• W3173641743 creator A5019547742 @default.
• W3173641743 creator A5019839737 @default.
• W3173641743 creator A5020324515 @default.
• W3173641743 creator A5020991100 @default.
• W3173641743 creator A5021091138 @default.
• W3173641743 creator A5021169879 @default.
• W3173641743 creator A5021197091 @default.
• W3173641743 creator A5022249692 @default.
• W3173641743 creator A5022264940 @default.
• W3173641743 creator A5022761066 @default.
• W3173641743 creator A5023053552 @default.
• W3173641743 creator A5023055484 @default.
• W3173641743 creator A5023215623 @default.
• W3173641743 creator A5023331706 @default.
• W3173641743 creator A5023572972 @default.
• W3173641743 creator A5023595745 @default.
• W3173641743 creator A5024469013 @default.
• W3173641743 creator A5024770626 @default.
• W3173641743 creator A5025011731 @default.
• W3173641743 creator A5025408460 @default.
• W3173641743 creator A5025647486 @default.
• W3173641743 creator A5025872990 @default.
• W3173641743 creator A5025925751 @default.
• W3173641743 creator A5026393946 @default.
• W3173641743 creator A5026465346 @default.
• W3173641743 creator A5026478909 @default.
• W3173641743 creator A5026610840 @default.
• W3173641743 creator A5026671787 @default.
• W3173641743 creator A5026699354 @default.
• W3173641743 creator A5027266775 @default.
• W3173641743 creator A5027287182 @default.
• W3173641743 creator A5027481104 @default.
• W3173641743 creator A5027646786 @default.
• W3173641743 creator A5027877389 @default.

• next